Reportlinker Adds Innovations in In-Vitro Diagnostics: New Technologies, Growth Opportunities, and the Future Market Outlook

NEW YORK--(Business Wire)--
Reportlinker.com announces that a new market research report is available in its
catalogue.

Reportlinker Adds Innovations in In-Vitro Diagnostics: New technologies, growth
opportunities, and the future market outlook

http://www.reportlinker.com/p0128172/Reportlinker-Adds-Innovations-in-In-Vitro-Diagnostics-New-technologies-growth-opportunities-and-the-future-market-outlook.html

Innovations in In-Vitro Diagnostics

New technologies, growth opportunities and the future market outlook

Report Overview

Clinical diagnostics is an attractive and growing industry, with the majority of
major diagnostic companies experiencing sales growth of over 10% in 2008,
despite significant pricing pressures. However, achieving market growth is
becoming increasingly challenging due to the difficulty in developing novel
diagnostics for new high value markets, or which can add appreciable clinical
benefit in existing markets.

`Innovations in In-Vitro Diagnostics` is a new report published by Business
Insights that provides an in-depth analysis of emerging opportunities and
potential clinical advances across the diagnostics markets of coronary heart
disease, heart failure, bacterial infections and viral infections. This report
explores the major trends and issues that are shaping the development of novel
diagnostics and assesses the future propsects of leading innovations. The market
segments with the greatest growth opportunities are identified and the
competitive landscape of the market is also assessed, with profiles of nine
major diagnostics companies, based on market presence, R&D focus, acquisitions,
historical sales and number of immunoanalyzers.

Key Findings

MRSA screening is the single most important new market for molecular
diagnostics. The market is currently valued at $1.2 billion in the US alone, and
could extend to $2.2 billion if screening technologies can be applied in smaller
hospitals, out-patients facilities and long-term care facilities.

Novel multiplex assays for respiratory viruses may become widely adopted if
effective antivirals become available, especially for the treatment of
respiratory syncytial virus infections in the elderly.

The growing prevalence of common chronic conditions will increase immunoassay
testing volumes. It is notable that one of the most promising new markets is for
troponin, a cardiac biomarker which was originally approved in the US in 1996.

Novel technologies with enhanced sensitivities will open up new areas of
research, although the clinical applications are still to be determined.
Conventional immunoassays and polymerase chain reaction are likely to remain the
most commercially significant technologies for the foreseeable future.

Negative pressure on growth is a barrier to the development of novel
immunoassays. New test approvals by the FDA have fallen from a peak of 867 in
1997 to 248 in 2008.

Use this report to...

• Identify which novel diagnostics offer the greatest potential clinical
advances within the cardiovascular, viral, and bacterial markets and compare
their efficacy against conventional diagnostic techniques.

• Understand the market dynamics that are shaping the in-vitro diagnostics
market with this report`s analysis of key issues including pricing, barriers to
innovation, factors driving testing volumes, regulatory changes and trends in
510(k) approvals.

• Evaluate the growth prospects of key new markets such as nosocomial infections
and respiratory virus multiplex panels, with this report`s estimates of
potential market sizes and drivers/resistors to market growth.

• Assess the competitive positions of leading diagnostics companies with this
report`s analysis of the performances, market presence and R&D focus of Roche,
Siemens Healthcare Diagnostics, Abbott, Ortho-Clinical Diagnostics, Beckman
Coulter, Becton Dickinson, Bio-Rad, bioMérieux and Inverness Medical Solutions.

Explore issues including

Incremental improvements in coronary heart disease detection. Novel markers in
development, such as PAPP-A and PGF, may add incremental improvements in risk
stratification and prognostic assessment. It is possible that new cardiac panels
will emerge, which combine markers of inflammation, ischemia, plaque instability
and necrosis.

Limited adoption of respiratory virus multiplex panels. Although several
multiplex RVPs have been launched, it appears unlikely that they will become
widely adopted until additional evidence demonstrates their cost-effectiveness.
The market for RVPs may expand more rapidly if effective anti-virals become
available, especially for respiratory syncytial virus.

Growth prospects in mature markets. The molecular diagnostic market has shown
steady growth since the start of the decade, serving a high unmet clinical need.
However, all the major existing submarkets, such as blood screening, sexually
transmitted disease testing and clinical virology are now mature with modest
growth prospects.

Discover

• What are the future growth prospects for the in-vitro diagnostics market?

• Which areas offer the most promising growth?

• Which segments promise the most innovation?

• Which companies are in the strongest position?

• Which smaller companies are attractive?

• What are the current unmet needs in the market?

• What are the greatest areas of market uncertainty?

To order this report:

Reportlinker Adds Innovations in In-Vitro Diagnostics: New technologies, growth
opportunities, and the future market outlook

http://www.reportlinker.com/p0128172/Reportlinker-Adds-Innovations-in-In-Vitro-Diagnostics-New-technologies-growth-opportunities-and-the-future-market-outlook.html

More market research reports here!

Reportlinker
Nicolas: nbo@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

Copyright Business Wire 2009